SUPPRESSION OF PANCREATIC ENDOCRINE TUMOUR SECRETION BY LONG-ACTING SOMATOSTATIN ANALOGUE

R. G. Long, T. E. Adrian, M. R. Brown, J. E. Rivier, A. J. Barnes, C. N. Mallinson, W. Vale, N. D. Christofides, S. R. Bloom

Research output: Contribution to journalArticlepeer-review

74 Citations (Scopus)

Abstract

A new long-acting octapeptide analogue of somatostatin, Des AA1,2,4,5,12,13 D Try8 somatostatin, has been tested in 8 patients with pancreatic endocrine tumours. The analogue given subcutaneously suppressed the tumour-derived hormones in patients with insulinomas, glucagonomas, and gastrinomas for up to 24 h. The prolonged action appeared to be the result of slow release from the injection site. No side-effects were observed. Studies of long-term administration of this new peptide are now warranted.

Original languageEnglish
Pages (from-to)764-767
Number of pages4
JournalThe Lancet
Volume314
Issue number8146
DOIs
Publication statusPublished - Oct 13 1979
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'SUPPRESSION OF PANCREATIC ENDOCRINE TUMOUR SECRETION BY LONG-ACTING SOMATOSTATIN ANALOGUE'. Together they form a unique fingerprint.

Cite this